Abstract: Provided are a computer program product, system, and method for recovering from a pending uncompleted reorganization of a data set managing data sets in a storage. In response an initiation of an operation to access a data set, an operation is initiated to complete a pending uncompleted reorganization of the data set in response to the data set being in a pending uncompleted reorganization state and no other process currently accessing the data set.

Abstract: A set-top box with enhanced features and system and method for use of the same are disclosed. In one embodiment of the set-top box, the set-top box is deployed to provide an interactive portal in a hospitality establishment having multiple rooms, such as a hotel. The set-top box generates a default interactive portal as well as a guest-specific interactive portal, which is generated from a guest configuration profile having information including guest identification, a guest channel preference presentation, and a guest service preference presentation with guest account information. The guest configuration profile may also enable the creation of a local area wireless network with substantially the same behavior as the guest's home wireless network. The guest configuration profile may further enable the control of in-room amenities, such as temperature control, lighting, shades, and availability, for example.

Abstract: Systems and methods for training and utilizing predictive models that ignore missing features in accordance with embodiments of the invention are illustrated. One embodiment includes a method for generating representations of inputs with missing values. The method includes steps for, at a single layer in a multi-layer model, receiving an input includes a set of one or more values for several features and identifying a missingness pattern of the input, wherein the missingness pattern indicates whether the set of values is missing a value for each of the several features. The method further includes determining a set of one or more transformation weights based on the missingness pattern and transforming the input based on the determined transformation weights.

Abstract: A method or preparing immunologically primed cancer cells using cancer cells collected from a patient includes treating the collected cancer cells, ex vivo, with a toxic concentration of a compound that modifies sphingolipid metabolism, wherein the toxic concentration is sufficient to induce immunogenic cell death in the cancer cells. In an embodiment, the compound is 3-(4-Chloro-phenyl)-adamantane-1-carboxylic acid(pyridin-4-ylmethyl)-amide compound or a pharmaceutically acceptable salt thereof. In an embodiment, the immunologically primed cancer cells overexpress calreticulin on their surface. In an embodiment, the cancer cells are solid tumor cells. In an embodiment, the cancer cells are circulating tumor cells. In an embodiment, the method further comprises harvesting at least a portion of the immunologically primed cancer cells; and suspending the cells in phosphate-buffered saline.

Abstract: Hinged assemblies, and children's products including at least one hinged assembly, include a base member and a hinged member operatively and pivotally coupled to the base member to define a hinge. The hinge is configured to release if an obstruction is positioned between the hinged member and the base member while the hinged member is being closed and if a closing torque is greater than or equal to a release torque. The hinge also may be configured to not release when an opening torque is applied when the hinged member is in its open position even when the opening torque is greater than the release torque.

Abstract: Hinged assemblies, and children's products including at least one hinged assembly, include a base member and a hinged member operatively and pivotally coupled to the base member to define a hinge. The hinge is configured to release if an obstruction is positioned between the hinged member and the base member while the hinged member is being closed and if a closing torque is greater than or equal to a release torque. The hinge also may be configured to not release when an opening torque is applied when the hinged member is in its open position even when the opening torque is greater than the release torque.

Abstract: The invention relates to prodrugs of hydroxyl-substituted adamantane compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

Abstract: Hinged assemblies, and children's products including at least one hinged assembly, include a base member and a hinged member operatively and pivotally coupled to the base member to define a hinge. The hinge is configured to release if an obstruction is positioned between the hinged member and the base member while the hinged member is being closed and if a closing torque is greater than or equal to a release torque. The hinge also may be configured to not release when an opening torque is applied when the hinged member is in its open position even when the opening torque is greater than the release torque.

Abstract: A utility trailer that includes a main compartment, an aft compartment, a hitch and jack assembly to attach it to a vehicle, and a number of components that will assist an individual in both shredding brush and branches as needed and also removing the resulting residue quickly and easily with use of various control boxes attached to the utility trailer. The trailer also includes a top-mounted shoot opening for throwing brush and debris into the utility trailer and conveyor belt system located within the main compartment for moving debris within the main compartment onto a pulled-out debris tray. A fold-down interior door is located within the main compartment and usually covers the conveyor belt system. Furthermore, a debris pusher blade is also located within the main compartment and can be utilized to push debris out of the main compartment by attached controls.

Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

Abstract: Hinged assemblies, and children's products including at least one hinged assembly, include a base member and a hinged member operatively and pivotally coupled to the base member to define a hinge. The hinge is configured to release if an obstruction is positioned between the hinged member and the base member while the hinged member is being closed and if a closing torque is greater than or equal to a release torque. The hinge also may be configured to not release when an opening torque is applied when the hinged member is in its open position even when the opening torque is greater than the release torque.

Abstract: The invention includes processes mainly for the treatment of a inflammatory diseases, such as inflammatory bowel disease, arthritis, atherosclerosis, asthma, allergy, inflammatory kidney disease, circulatory shock, multiple sclerosis, chronic obstructive pulmonary disease, skin inflammation, periodontal disease, psoriasis and T cell-mediated diseases of immunity, including allergic encephalomyelitis, allergic neuritis, transplant allograft rejection, graft versus host disease, myocarditis, thyroiditis, nephritis, systemic lupus erthematosus, and insulin-dependent diabetes mellitus. The processes involve treating a patient with a pharmaceutical composition containing an active ingredient that inhibits the activity of sphingosine kinase.

Abstract: Methods of treating or preventing a disease or disorder in a subject are provided by the present invention which include administering a composition including a therapeutically effective amount of a protein kinase C (PKC) zeta inhibitor. A disease or disorder treated or prevented by administration of a PKC zeta inhibitor is characterized by abnormal vascular permeability. Diseases or disorders treated or prevented by administration of a composition including a therapeutically effective amount of a PKC zeta inhibitor include cancer, an ischemic condition and microvascular complications of a systemic or local condition in the subject, such as diabetes and/or diabetic macular edema. Additionally, methods of inhibiting PKC zeta are provided which include incubating PKC zeta in vivo, in vitro and/or in silico with a PKC zeta inhibitor.

Abstract: Ischemia-reperfusion injury remains a primary cause of morbidity and mortality in individuals who experience disruption of normal blood flow to one or more major organs. For example, there are no clinically proven strategies that prevent acute renal failure following cardiac surgery. The present invention provides a variety of methods for the treatment or prevention of ischemia-reperfusion injury. In one aspect of the invention, a method for treating or preventing ischemia-reperfusion injury includes administering to a subject an effective amount of a sphingosine kinase inhibitor. Sphingosine kinase inhibitors are very effective in the protection against IR-induced acute renal failure and liver failure. Moreover, the effects occur very early after administration, requiring only a very short time of treatment. Toxicology studies with sphingosine kinase inhibitors demonstrate that they have low toxicity, even in long-term treatment.

Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

Abstract: The invention relates to prodrugs of hydroxyl-substituted adamantane compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

Abstract: The disclosure relates to inhibitors of Pim-1 and/or Pim-2 protein kinase, to compositions comprising one or more inhibitors of Pim-1 and/or Pim-2 protein kinase, and to methods for treating cancer.

Abstract: The invention relates to compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.